In this regard, the S100A4 inhibitor niclosamide is currently in phase II clinical trial for metastatic colorectal cancer (NCT02519582) and prostate cancer (NCT02807805) and has completed phase I trial for prostate cancer (NCT02532114) [43,44,45]. The gene discussed is S100A4; the disease is prostate carcinoma.